Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,708 Mln
Revenue (TTM)
$6 Mln
Net Profit (TTM)
$-116 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.1
Industry P/E
--
EV/EBITDA
-11.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.5
Face value
--
Shares outstanding
67,049,500
CFO
$-378.54 Mln
EBITDA
$-294.80 Mln
Net Profit
$-731.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
| 54.2 | 2.6 | 87.8 | 86.9 | 46.7 | 7.0 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
| 60.6 | 2.8 | 168.8 | -55.3 | -64.6 | -34.2 | -59.5 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
40.4 | 2,708.1 | 5.9 | -243.2 | -4,288.1 | -60.9 | -- | 3.1 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin... receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG. Read more
Pres, CEO & Director
Mr. Eric L. Dobmeier J.D.
Pres, CEO & Director
Mr. Eric L. Dobmeier J.D.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Chinook Therapeutics Inc (KDNY) is $40.39 (NASDAQ) as of 18-Aug-2023 09:30 EDT. Chinook Therapeutics Inc (KDNY) has given a return of 46.67% in the last 3 years.
Since, TTM earnings of Chinook Therapeutics Inc (KDNY) is negative, P/E ratio is not available.
The P/B ratio of Chinook Therapeutics Inc (KDNY) is 3.06 times as on 18-Aug-2023, a 22 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-9.82
|
4.10
|
|
2021
|
-8.64
|
1.93
|
|
2020
|
-8.22
|
2.00
|
|
2019
|
-0.81
|
-0.92
|
|
2018
|
-0.88
|
0.62
|
The 52-week high and low of Chinook Therapeutics Inc (KDNY) are Rs -- and Rs -- as of 03-Apr-2026.
Chinook Therapeutics Inc (KDNY) has a market capitalisation of $ 2,708 Mln as on 18-Aug-2023. As per SEBI classification, it is a company.
Before investing in Chinook Therapeutics Inc (KDNY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.